Latest Conference Articles

July 1st 2016, 6:28pm

ESMO Gastrointestinal Cancers Congress

Dr. Navesh K. Sharma, associate professor of Radiology in the Division of Radiology and Oncology at Penn State Hershey Medical Center and section chief of Radiation Oncology at the Penn State Health St. Joseph Cancer Center, discusses that age should not be a deciding factor in giving internal radiation to patients with liver cancer.

July 1st 2016, 4:11pm

ESMO Gastrointestinal Cancers Congress

Dr. Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the major impact that regorafenib (Stivarga) will have for the treatment of hepatocellular carcinoma (HCC).

July 1st 2016, 2:18pm

ESMO Gastrointestinal Cancers Congress

Dr. Adam Bass, MD, Dana-Farber Cancer Institute, discusses the causes for different types of gastric cancer.

July 1st 2016, 12:32am

ESMO Gastrointestinal Cancers Congress

Patients with stage Ib-IVa resectable gastric adenocarcinoma undergoing surgery with curative intent had similar survival outcomes regardless of whether they received chemotherapy or chemoradiotherapy after surgery.

June 30th 2016, 7:35pm

ESMO Gastrointestinal Cancers Congress

Eileen M. O’Reilly, MD, associate director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center, discusses factors that patients and oncologists should consider when developing a treatment plan for pancreatic cancer.

June 30th 2016, 6:17pm

ESMO Gastrointestinal Cancers Congress

Daniel Sargent, PhD, professor of Oncology and Biostatistics, Mayo Clinic in Rochester, Minnesota, discusses the IDEA initiative, which is an international study to examine if patients with colon cancer would benefit from reducing the duration of adjuvant therapy from 3 months to 6 months to reduce side effects and cost.

June 30th 2016, 6:02pm

ESMO Gastrointestinal Cancers Congress

Adding MM-398 (irinotecan liposome injection; nal-IRI; Onivyde) to 5-fluorouracil and leucovorin had no negative effect on quality of life while significantly improving overall survival in patients with metastatic pancreatic cancer.

June 30th 2016, 5:25pm

ESMO Gastrointestinal Cancers Congress

John L. Marshall, MD, chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, clinical research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses the difference between squamous and adenocarcinoma in esophageal and gastric cancer.

June 29th 2016, 11:50pm

ESMO Gastrointestinal Cancers Congress

Combined inhibition of the PD-L1/PD-1 axis with atezolizumab (Tecentriq) and the MEK pathway with cobimetinib (Cotellic) showed promising clinical activity and a good safety profile in heavily pretreated patients with microsatellite stable metastatic colorectal cancer.

June 28th 2016, 8:02pm

ESMO Gastrointestinal Cancers Congress

Second-line treatment with regorafenib (Stivarga) improved overall survival by 2.8 months compared with placebo for patients with unresectable hepatocellular carcinoma who progressed on sorafenib (Nexavar).

June 13th 2016, 1:18am

European Hematology Association Congress

Inotuzumab ozogamicin demonstrated significantly improved progression-free survival and complete remission rates compared with chemotherapy for patients with relapsed or refractory acute lymphoblastic leukemia.

June 12th 2016, 11:58pm

European Hematology Association Congress

Final 5-year efficacy and safety data from the phase III COMFORT-I trial confirm previous findings that ruxolitinib confers a significant benefit in patients with intermediate-2 and high-risk myelofibrosis.

June 12th 2016, 9:45pm

European Hematology Association Congress

Patients with acute myeloid leukemia who are cured after allogeneic hematopoietic stem cell transplantation produce antibodies that destroy leukemia cells.

June 12th 2016, 4:48pm

European Hematology Association Congress

June 12th 2016, 3:50pm

European Hematology Association Congress

June 12th 2016, 12:54am

European Hematology Association Congress

Combining the CD38-targeted antibody daratumumab with lenalidomide and dexamethasone reduced the risk of disease progression by 63% versus lenalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma, according to findings from the phase III POLLUX (MMY3003) trial.

June 12th 2016, 12:45am

European Hematology Association Congress

A host of novel agents that target distinct molecular targets are pushing complete remission rates beyond historical boundaries for patients with acute myeloid leukemia.

June 12th 2016, 12:10am

European Hematology Association Congress

Frontline treatment with the CD33-directed antibody-drug conjugate vadastuximab talirine plus a hypomethylating agent induced deep and durable remissions for older patients with acute myeloid leukemia.

June 11th 2016, 10:29pm

European Hematology Association Congress

​Christian Gisselbrecht, MD, a Professor of Haematology in the Haemato-Oncology Department of Hôpital Saint-Louis, at Diderot University, Paris, discusses stratifying refractory disease in aggressive diffuse large b-cell lymphoma (DLBCL).

June 11th 2016, 2:43pm

European Hematology Association Congress

​Wojciech Jurczak, MD Head of Lymphoma, Department of Hematology, Jagiellonian University, Kopernika, Poland, discuses a subgroup analyses of diffuse large b-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).